A panelist discusses how neurokinin-targeted therapies can be strategically combined with existing treatments to address multiple vasomotor symptoms (VMS) while highlighting their positive impact on ...

Astellas remains on course to be the first drugmaker to bring a new non-hormonal therapy for symptoms of menopause to market, after the FDA started a review of its orally-active neurokinin-3 (NK3 ...

and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, and atopic dermatitis. The company’s pipeline products also include ...

The table below is a review of notable updates that occurred in January 2025 for investigational products in development.